Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

Secondary offering usually precedes imminently good news: all 400 P2 subjects receive 1st dose; many already receive 2nd dose. Cash, ST investments $412M 12/31/20. All 80 P1 0.5mg subjects receive 2mg 3rd dose. BofA Securities, Jefferies, Cantor, Oppenheimer may upgrade stock. NHP challenge result from OWS, CSIRO, England Public Health. REVEAL2 P3 VGX-3100 Recruiting to finish soon.

The Company preliminarily estimates that its cash, cash equivalents and short-term investments as of December 31, 2020 was approximately $412 million and that it had 186,851,493 shares of common stock outstanding as of December 31, 2020.

INO 16:31 01/20/21 Inovio announces $150M offering of common stock Inovio announced that it has commenced an underwritten public offering of $150M of shares of its common stock. Inovio intends to use the net proceeds from this offering for the development of its clinical pipeline, including clinical development expenses relating to INO-4800 and research and development expenses, and for general corporate purposes, including working capital and general and administrative expenses. BofA Securities, Jefferies and Cantor are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager for the offering.